Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History SRPT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics SRPT

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Sarepta Therapeutics Inc

SRPT
Current price
18.17 USD -0.78 USD (-4.14%)
Last closed 19.07 USD
ISIN US8036071004
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 1 873 651 072 USD
Yield for 12 month -88.05 %
1Y
3Y
5Y
10Y
15Y
SRPT
21.11.2021 - 28.11.2021

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. Address: 215 First Street, Cambridge, MA, United States, 02142

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

48.04 USD

P/E Ratio

Dividend Yield

Financials SRPT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures SRPT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+1 901 979 000 USD

Last Year

+1 243 336 000 USD

Current Quarter

+744 856 000 USD

Last Quarter

+658 412 000 USD

Current Year

+1 582 880 000 USD

Last Year

+1 092 993 000 USD

Current Quarter

+607 292 000 USD

Last Quarter

+515 653 000 USD
EBITDA -78 252 000 USD
Operating Margin TTM -40.33 %
Price to Earnings
Return On Assets TTM -2.19 %
PEG Ratio 159.25
Return On Equity TTM -23.61 %
Wall Street Target Price 48.04 USD
Revenue TTM 2 233 370 880 USD
Book Value 11.63 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 80.20 %
Dividend Yield
Gross Profit TTM 449 692 992 USD
Earnings per share -2.64 USD
Diluted Eps TTM -2.64 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY 245.20 %
Profit Margin -11.12 %

Stock Valuation SRPT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 9.84
Enterprise Value Revenue 1.22
Price Sales TTM 0.84
Enterprise Value EBITDA 99.06
Price Book MRQ 1.67

Technical Indicators SRPT

For 52 Weeks

16.88 USD 154.13 USD
50 Day MA 34.07 USD
Shares Short Prior Month 9 885 949
200 Day MA 89.05 USD
Short Ratio 2.61
Shares Short 14 683 653
Short Percent 11.79 %